Trial Profile
A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- 19 Nov 2014 Planned End Date changed from 1 Aug 2013 to 1 Aug 2015 according to ClinicalTrials.gov record.
- 14 Jun 2013 Results presented at the 18th Congress of the European Haematology Association.
- 13 Dec 2011 Final results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.